SCHEMBL4957575

SCHEMBL4957575

O=P(O)(O)Oc1ccc(CO)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 2/20 0.56
BLM P54132 1/20 0.53
INPPL1 O15357 7/20 0.50
INPP5A Q14642 6/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CYP2C19 P33261 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
LTA4H P09960 1/20 0.47
PPARG P37231 2/20 0.43
PPARA Q07869 2/20 0.43
AKT1 P31749 1/20 0.40
INPP5B P32019 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PTPN1 P18031 1/20 0.38
CA12 O43570 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28538119 0.87 CES2 (0.50) SRCBLMCA1CA2CYP2C19
SCHEMBL14608595 0.85 BLM (0.81) SRCBLMINPPL1INPP5ACA1
SCHEMBL1982061 0.84 TSHR (0.52) SRCBLMCA1CA2CYP2C19
SCHEMBL8386547 0.83 SRC (0.52) SRCBLMINPPL1INPP5ACA1
SCHEMBL329313 0.83 SRC (0.75) SRCBLMINPPL1INPP5ACA1
SCHEMBL21585511 0.83 INPPL1 (0.50) SRCBLMINPPL1INPP5ACA1
Ammonia Solution, Strong SCHEMBL10714477 0.81 SRC (0.71) SRCBLMINPPL1INPP5ACA1
SCHEMBL3083991 0.81 SRC (0.54) SRCBLMINPPL1INPP5ACA1
SCHEMBL10432958 0.81 SRC (0.54) SRCBLMINPPL1INPP5ACA1
SCHEMBL22356177 0.81 SRC (0.54) SRCBLMINPPL1INPP5ACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117820636-B Enzyme-responsive cytotoxic polyamino acid, and preparation method and application thereof 中国科学院长春应用化学研究所 2024-05-24 CN claimed
CN-117820636-A Enzyme-responsive cytotoxic polyamino acid, and preparation method and application thereof 中国科学院长春应用化学研究所 2024-04-05 CN claimed
CN-107868187-B Preparation method of low-hydration-heat polycarboxylate superplasticizer 科之杰新材料集团有限公司 2020-05-08 CN claimed
CN-107987235-B Preparation method of low-hydration-heat anti-cracking polycarboxylate superplasticizer 科之杰新材料集团有限公司 2020-03-06 CN claimed
CN-107987228-B Preparation method of low-hydration-heat early-strength polycarboxylate superplasticizer 科之杰新材料集团有限公司 2020-03-06 CN claimed
CN-117820636-B Enzyme-responsive cytotoxic polyamino acid, and preparation method and application thereof 中国科学院长春应用化学研究所 2024-05-24 CN disclosed
CN-117820636-A Enzyme-responsive cytotoxic polyamino acid, and preparation method and application thereof 中国科学院长春应用化学研究所 2024-04-05 CN disclosed
US-11254695-B2 Soluble C5aR antagonists CHEMOCENTRYX, INC. (US) 2022-02-22 US disclosed
EP-3439658-B1 SOLUBLE C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2021-11-24 EP disclosed
US-20200262853-A1 SOLUBLE C5aR ANTAGONISTS CHEMOCENTRYX, INC. 2020-08-20 US disclosed
CN-107868187-B Preparation method of low-hydration-heat polycarboxylate superplasticizer 科之杰新材料集团有限公司 2020-05-08 CN disclosed
CN-107987235-B Preparation method of low-hydration-heat anti-cracking polycarboxylate superplasticizer 科之杰新材料集团有限公司 2020-03-06 CN disclosed
US-10329314-B2 Soluble C5aR antagonists CHEMOCENTRYX, INC. (US) 2019-06-25 US disclosed
EP-3439658-A2 SOLUBLE C5aR ANTAGONISTS ChemoCentryx, Inc. (US) 2019-02-13 EP disclosed
US-20190010177-A1 SOLUBLE C5aR ANTAGONISTS CHEMOCENTRYX, INC. 2019-01-10 US disclosed
WO-2017176620-A2 SOLUBLE C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2017-10-12 WO disclosed
US-20170283446-A1 SOLUBLE C5aR ANTAGONISTS CHEMOCENTRYX, INC. 2017-10-05 US disclosed
WO-2015140575-A1 ENZYME DETECTION METHOD ATLAS GENETICS LIMITED (GB) 2015-09-24 WO disclosed
EP-1885875-A2 LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS PROMEGA CORPORATION (US) 2008-02-13 EP disclosed
WO-2006130551-A2 LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS PROMEGA CORPORATION (US) 2006-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200262853-A1 SOLUBLE C5aR ANTAGONISTS C5AR1, C3AR1, C5AR2 SRC 1195/4885BLM 3869/4885INPPL1 2671/4885
US-20170283446-A1 SOLUBLE C5aR ANTAGONISTS C5AR1, C3AR1, C5AR2 SRC 1195/4885BLM 3869/4885INPPL1 2671/4885
US-20190010177-A1 SOLUBLE C5aR ANTAGONISTS C5AR1, C3AR1, C5AR2 SRC 1195/4885BLM 3869/4885INPPL1 2671/4885
US-10329314-B2 Soluble C5aR antagonists C5AR1, C3AR1, C5AR2 SRC 1195/4885BLM 3869/4885INPPL1 2671/4885
US-11254695-B2 Soluble C5aR antagonists C5AR1, C3AR1, C5AR2 SRC 1195/4885BLM 3869/4885INPPL1 2671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.